首页|Nanomedicine targeting ferroptosis to overcome anticancer therapeutic resistance
Nanomedicine targeting ferroptosis to overcome anticancer therapeutic resistance
扫码查看
点击上方二维码区域，可以放大扫码查看
原文链接
万方数据
维普
A potential reason for the failure of tumor therapies is treatment resistance.Resistance to chemotherapy,radiotherapy,and immunotherapy continues to be a major obstacle in clinic,resulting in tumor recurrence and metastasis.The major mechanisms of therapy resistance are inhibitions of cell deaths,like apoptosis and necrosis,through drug inactivation and excretion,repair of DNA damage,tumor heterogeneity,or changes in tumor microenvironment,etc.Recent studies have shown that ferroptosis play a major role in therapies resistance by inducing phospholipid peroxidation and iron-dependent cell death.Some ferroptosis inducers in combination with clinical treatment techniques have been used to enhance the effect in tumor therapy.Notably,versatile ferroptosis nanoinducers exhibit an extensive range of functions in reversing therapy resistance,including directly triggering ferroptosis and feedback regulation.Herein,we provide a detailed description of the design,mechanism,and therapeutic application of ferroptosis-mediated synergistic tumor therapeutics.We also discuss the prospect and challenge of nanomedicine in tumor therapy resistance by regulating ferroptosis and combination therapy.
Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation,Guangdong-Hong Kong Joint Laboratory for RNA Medicine,Medical Research Center,Sun Yat-sen Memorial Hospital,Sun Yat-sen University,Guangzhou 510120,China
Nanhai Translational Innovation Center of Precision Immunology,Sun Yat-sen Memorial Hospital,Sun Yat-sen University,Foshan 528200,China
National Natural Science Foundation of ChinaChina Postdoctoral Science Foundation funded projectGuangdong Provincial Fund for Distinguished Young Scholars
万方数据
维普
